AstraZeneca's Andexxa is the latest product cleared through accelerated approval to remain dangling after failing to convert to full approval. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
